Among immunotherapies, the programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been shown to be the primary treatment for advanced lung cancer (9–11). Here, CD274 is linked to lung carcinoma.